Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ME Therapeutics Holdings, Inc. ( (TSE:METX) ) has issued an announcement.
ME Therapeutics Holdings Inc. announced that its subsidiary is receiving advisory services and up to $140,000 in funding from the National Research Council of Canada Industrial Research Assistance Program to advance its mRNA therapeutic program. This initiative aims to develop treatments targeting myeloid cell biology for cancer and inflammatory diseases, with promising preclinical results in colorectal cancer models, potentially enhancing the company’s position in the immuno-oncology field.
More about ME Therapeutics Holdings, Inc.
Myeloid Enhancement (ME) Therapeutics is a publicly listed, preclinical stage biotechnology company based in Vancouver, focused on discovering and developing novel immuno-oncology therapeutics. The company targets immune suppression in cancer by overcoming the suppressive effects of myeloid cells to enhance anti-cancer immunity.
Average Trading Volume: 300
Technical Sentiment Signal: Buy
See more data about METX stock on TipRanks’ Stock Analysis page.